Table 3.
FEV1 at study entry, follow-up and annual decline by number of respiratory symptoms among women, men and all participants
| FEV1pp pre-BD at study entry | FEV1pp pre-BD at follow-up | Annual decline in FEV1pp | ||
| Women | ||||
| None or 1 symptoms | n=206 | 92.3 (11.8) | 92.8 (15.1) | 0.040 (0.580) |
| 2 symptoms | n=157 | 89.5 (12.7) | 90.2 (15.2) | 0.048 (0.611) |
| 3 symptoms | n=127 | 88.8 (12.8) | 87.9 (16.0) | −0.035 (0.666) |
| 4 symptoms | n=55 | 85.5 (13.4) | 87.0 (15.8) | 0.084 (0.550) |
| P value | 0.001 | 0.011 | 0.553 | |
| Men | ||||
| None or 1 symptoms | n=216 | 89.2 (14.1) | 85.0 (14.8) | −0.207 (0.583) |
| 2 symptoms | n=110 | 84.6 (14.4) | 83.2 (15.3) | −0.044 (0.670) |
| 3 symptoms | n=87 | 83.1 (16.1) | 78.0 (19.0) | −0.287 (0.606) |
| 4 symptoms | n=19 | 83.3 (15.0) | 79.0 (19.3) | −0.303 (0.772) |
| P value | 0.002 | 0.005 | 0.031 | |
| Total | ||||
| None or 1 symptoms | n=422 | 90.7 (13.1) | 88.8 (15.4) | −0.086 (0.594) |
| 2 symptoms | n=267 | 87.5 (13.6) | 87.3 (15.6) | 0.010 (0.636) |
| 3 symptoms | n=214 | 86.5 (14.5) | 83.8 (17.9) | −0.137 (0.652) |
| 4 symptoms | n=74 | 84.9 (13.7) | 84.9 (17.0) | −0.016 (0.632) |
| P value | <0.001 | 0.002 | 0.052 | |
Results presented as mean (SD) and p values from ANOVA in bold figures indicate p<0.05.
Included respiratory symptoms: recurrent wheeze, dyspnoea, longstanding cough, productive cough.
ANOVA, analysis of variance; FEV1, forced expiratory volume in 1 s; Pre-BD, pre-bronchodilatation.